Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials
Abstract D-amino acid oxidase inhibitors (DAOI) have demonstrated potential therapeutic benefits for schizophrenia and cognitive impairment; however, existing studies present conflicting results. This meta-analysis aimed to assess the symptomatic and cognitive effects of DAOI on the treatment of sch...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Schizophrenia |
| Online Access: | https://doi.org/10.1038/s41537-025-00604-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850278254505623552 |
|---|---|
| author | Chun-Hung Chang Yu-Der Hsia Wen-Chun Liu Jia-Hau Lee Chieh-Hsin Lin Hsien-Yuan Lane |
| author_facet | Chun-Hung Chang Yu-Der Hsia Wen-Chun Liu Jia-Hau Lee Chieh-Hsin Lin Hsien-Yuan Lane |
| author_sort | Chun-Hung Chang |
| collection | DOAJ |
| description | Abstract D-amino acid oxidase inhibitors (DAOI) have demonstrated potential therapeutic benefits for schizophrenia and cognitive impairment; however, existing studies present conflicting results. This meta-analysis aimed to assess the symptomatic and cognitive effects of DAOI on the treatment of schizophrenia. An electronic search was conducted using PubMed, Cochrane Systematic Reviews, and the Cochrane Central Register of Controlled Clinical Trials for double-blinded, randomized controlled trials evaluating DAOI for the treatment of schizophrenia. Published trials up to November 2024 were included in the analysis. A random-effects model was employed to pool data for comparing the treatment effects of DAOI. Participants diagnosed with schizophrenia were recruited. Clinical and cognitive improvements were compared between baseline and post-DAOI treatment using standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity across the trials was assessed through funnel plots and the I² statistic. A total of five trials with 530 participants met the inclusion criteria. Four trials utilized sodium benzoate, while one trial employed luvadaxistat. The Positive and Negative Syndrome Scale (PANSS) was used in all studies to evaluate clinical symptoms, with four studies also assessed cognitive function. This analysis highlighted that DAOI surpassed the comparator in reducing the scores of PANSS total (SMD = −0.270, P = 0.035), PANSS positive (SMD = −0.399, P = 0.022), PANSS negative (SMD = −0.171, P = 0.026), and PANSS general psychopathology (SMD = −0.180, P = 0.019). Subgroup analyses identified significant effects in trials using sodium benzoate (SMD = 0.368, P = 0.021). Moreover, DAOI showed greater improvements in cognitive functions (SMD = 0.359, P = 0.017), with a better effect correlated with more female participants. The findings of this meta-analysis suggest that DAOI may be effective in improving clinical symptoms and cognitive function in patients with schizophrenia. Further studies with larger sample sizes are needed to confirm these results. |
| format | Article |
| id | doaj-art-16f49d104c2d4d46a3bf842cc534bc06 |
| institution | OA Journals |
| issn | 2754-6993 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Schizophrenia |
| spelling | doaj-art-16f49d104c2d4d46a3bf842cc534bc062025-08-20T01:49:35ZengNature PortfolioSchizophrenia2754-69932025-05-0111111010.1038/s41537-025-00604-2Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trialsChun-Hung Chang0Yu-Der Hsia1Wen-Chun Liu2Jia-Hau Lee3Chieh-Hsin Lin4Hsien-Yuan Lane5An Nan Hospital, China Medical UniversityAn Nan Hospital, China Medical UniversityAn Nan Hospital, China Medical UniversityAn Nan Hospital, China Medical UniversityGraduate Institute of Biomedical Sciences, China Medical UniversityGraduate Institute of Biomedical Sciences, China Medical UniversityAbstract D-amino acid oxidase inhibitors (DAOI) have demonstrated potential therapeutic benefits for schizophrenia and cognitive impairment; however, existing studies present conflicting results. This meta-analysis aimed to assess the symptomatic and cognitive effects of DAOI on the treatment of schizophrenia. An electronic search was conducted using PubMed, Cochrane Systematic Reviews, and the Cochrane Central Register of Controlled Clinical Trials for double-blinded, randomized controlled trials evaluating DAOI for the treatment of schizophrenia. Published trials up to November 2024 were included in the analysis. A random-effects model was employed to pool data for comparing the treatment effects of DAOI. Participants diagnosed with schizophrenia were recruited. Clinical and cognitive improvements were compared between baseline and post-DAOI treatment using standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity across the trials was assessed through funnel plots and the I² statistic. A total of five trials with 530 participants met the inclusion criteria. Four trials utilized sodium benzoate, while one trial employed luvadaxistat. The Positive and Negative Syndrome Scale (PANSS) was used in all studies to evaluate clinical symptoms, with four studies also assessed cognitive function. This analysis highlighted that DAOI surpassed the comparator in reducing the scores of PANSS total (SMD = −0.270, P = 0.035), PANSS positive (SMD = −0.399, P = 0.022), PANSS negative (SMD = −0.171, P = 0.026), and PANSS general psychopathology (SMD = −0.180, P = 0.019). Subgroup analyses identified significant effects in trials using sodium benzoate (SMD = 0.368, P = 0.021). Moreover, DAOI showed greater improvements in cognitive functions (SMD = 0.359, P = 0.017), with a better effect correlated with more female participants. The findings of this meta-analysis suggest that DAOI may be effective in improving clinical symptoms and cognitive function in patients with schizophrenia. Further studies with larger sample sizes are needed to confirm these results.https://doi.org/10.1038/s41537-025-00604-2 |
| spellingShingle | Chun-Hung Chang Yu-Der Hsia Wen-Chun Liu Jia-Hau Lee Chieh-Hsin Lin Hsien-Yuan Lane Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials Schizophrenia |
| title | Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials |
| title_full | Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials |
| title_fullStr | Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials |
| title_full_unstemmed | Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials |
| title_short | Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials |
| title_sort | symptomatic and cognitive effects of d amino acid oxidase inhibitors in patients with schizophrenia a meta analysis of double blind randomized controlled trials |
| url | https://doi.org/10.1038/s41537-025-00604-2 |
| work_keys_str_mv | AT chunhungchang symptomaticandcognitiveeffectsofdaminoacidoxidaseinhibitorsinpatientswithschizophreniaametaanalysisofdoubleblindrandomizedcontrolledtrials AT yuderhsia symptomaticandcognitiveeffectsofdaminoacidoxidaseinhibitorsinpatientswithschizophreniaametaanalysisofdoubleblindrandomizedcontrolledtrials AT wenchunliu symptomaticandcognitiveeffectsofdaminoacidoxidaseinhibitorsinpatientswithschizophreniaametaanalysisofdoubleblindrandomizedcontrolledtrials AT jiahaulee symptomaticandcognitiveeffectsofdaminoacidoxidaseinhibitorsinpatientswithschizophreniaametaanalysisofdoubleblindrandomizedcontrolledtrials AT chiehhsinlin symptomaticandcognitiveeffectsofdaminoacidoxidaseinhibitorsinpatientswithschizophreniaametaanalysisofdoubleblindrandomizedcontrolledtrials AT hsienyuanlane symptomaticandcognitiveeffectsofdaminoacidoxidaseinhibitorsinpatientswithschizophreniaametaanalysisofdoubleblindrandomizedcontrolledtrials |